Company Profile
Biomea Fusion Stock Price, News & Analysis
- Ticker:
- BMEA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.25 USD (-0.79%)
Close
Last updated: August 6, 2026
99.1M USD
Market cap
Why the stock is moving
The latest company update was “Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights”. BMEA changed 0.79% and closed at $1.25 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Metabolic Disease Company
Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity.
Icovamenib
Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes.
COVALENT Program
COVALENT-211 and COVALENT-212 are Phase 2 studies in different type 2 diabetes populations.
BMF-650
BMF-650 is an oral GLP-1 receptor agonist in early clinical development for obesity.
Future catalysts
Initial 28-day weight-reduction data from the Phase 1 BMF-650 study are expected in the second quarter of 2026.
Twenty-six-week topline data from COVALENT-211 and COVALENT-212 are expected in the fourth quarter of 2026.
Recent news
- 01
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Source: Biomea Fusion
- 02
- 03
- 04
Biomea Fusion to Participate at Upcoming Investor Conferences
Source: Biomea Fusion
- 05
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Source: Biomea Fusion
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biomea Fusion (BMEA)?
Biomea Fusion (BMEA) most recently closed at 1.25 USD, a -0.79% move versus the previous session.
What is the market cap of Biomea Fusion (BMEA)?
Biomea Fusion currently has a market capitalization of 99.1M USD on BioPharmSignal.
What does Biomea Fusion do?
Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and COVALENT-212 are Phase 2...
On which exchange is BMEA stock listed?
Biomea Fusion (BMEA) is associated with NASDAQ, United States, Biopharma.
What is COVALENT-211?
Twenty-six-week topline data from COVALENT-211 and COVALENT-212 are expected in the fourth quarter of 2026.
Which conditions is Biomea Fusion targeting with COVALENT-211?
Biomea Fusion is associated with metabolic disease, obesity, diabetes based on its company overview and current catalyst commentary.
How does Biomea Fusion describe recent progress with COVALENT-211?
Twenty-six-week topline data from COVALENT-211 and COVALENT-212 are expected in the fourth quarter of 2026.
What is COVALENT-212?
COVALENT Program COVALENT-211 and COVALENT-212 are Phase 2 studies in different type 2 diabetes populations.